Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
The CYBN news page on Stock Titan provides an archive of news releases and updates related to Cybin Inc., a Phase 3 clinical-stage neuropsychiatry and pharmaceutical company focused on developing next-generation treatment options for mental health conditions. These news items come directly from the company’s public communications and are also referenced in its Form 6-K filings with the U.S. Securities and Exchange Commission.
Readers can find coverage of Cybin’s clinical development programs, including updates on its lead candidates CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. News releases describe milestones such as trial enrollment progress, regulatory approvals to initiate studies in various countries, and participation in healthcare and investor conferences.
The news feed also includes information on Cybin’s capital markets activity, such as registered direct offerings of common shares and pre-funded warrants, the establishment and use of an at-the-market equity program, and the company’s stated intentions for the use of proceeds, including repayment of convertible debentures and funding of its clinical programs. Corporate updates, including plans to transfer its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market and the associated change in ticker symbol from CYBN to HELP, are documented in detail.
Because Cybin files many of these news releases as exhibits to Form 6-K, the CYBN news page serves as a convenient way to follow the narrative of its clinical progress, financing decisions, and listing changes over time. Investors and researchers can use this archive to review how the company describes its strategy in neuropsychiatry, its geographic operations in Canada, the United States, the United Kingdom, and Ireland, and its stated commitment to rigorous scientific research and regulatory compliance for its investigational compounds.
Helus Pharma (Nasdaq: HELP) announced its U.S. listing migration to the Nasdaq Global Market and ongoing trading on Cboe Canada under HELP, and said it will operate under the business name Helus Pharma. The company highlighted two lead programs: HLP003, a Phase 3 NSA with Breakthrough Therapy Designation for adjunctive major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder with a topline readout expected in Q1 2026. The company cited >350 filed patents (100+ granted) and said commercialization preparations for HLP003 are underway, subject to receipt of necessary approvals.
Cybin (NYSE American: CYBN) launched an at-the-market equity program (ATM) to issue and sell up to US$100,000,000 of common shares from treasury through Cantor Fitzgerald and Cantor Fitzgerald Canada.
Sales will be made at prevailing market prices on Cboe Canada, a U.S. exchange or other listed marketplaces, under a Distribution Agreement dated December 30, 2025. The ATM is effective until shares are sold or October 17, 2027, and proceeds are intended for growth opportunities and working capital. The program is qualified by a Prospectus Supplement to a Base Shelf Prospectus that allows offerings up to C$1.7 billion through October 17, 2027.
Cybin (NYSE American: CYBN) announced a voluntary transfer of its U.S. listing to the Nasdaq Global Market and a corporate rebrand to Helus Pharma.
Common shares will cease trading on NYSE American at market close on January 2, 2026 and commence trading on Nasdaq at market open on January 5, 2026 under the new ticker HELP. The company will continue to trade on Cboe Canada under HELP starting January 5, 2026.
Cybin (NYSE:CYBN) reported Q2 FY2026 results and business highlights on November 13, 2025. Key items include a completed registered direct offering of US$175 million, a pro forma cash position of US$248 million as of September 30, 2025, and repayment of outstanding convertible debentures (total cash repayment ~US$22.8 million).
Clinical progress: completed enrollment in the CYB004 Phase 2 study for GAD with topline data expected in Q1 2026; ongoing dosing in the CYB003 Phase 3 APPROACH study with topline expected in Q4 2026; EMBRACE Phase 3 initiation expected in Q4 2025 with approvals in multiple countries. IP: >100 granted patents and >250 pending applications expiring at least through 2041.
Cybin (NYSE American:CYBN) announced that George Tziras, Chief Business Officer, will present at the Jefferies Global Healthcare Conference in London on November 17, 2025. The live webcast is scheduled for Monday, November 17, 2025 at 12:30 p.m. GMT (7:30 a.m. ET). Investors can access the live webcast via the company’s webcast link, and an archived replay will be available on the company’s investor relations Events & Presentations page.
Cybin (NYSE American: CYBN) will report second quarter results for the period ended September 30, 2025 and provide a business update on Thursday, November 13, 2025.
The company will host a conference call and webcast at 8:00 a.m. ET on November 13, 2025. Dial-in numbers are 800-245-3047 (U.S. toll free) and 203-518-9765 (international) with Conference ID CYBN1113. A live webcast requires registration and an archived webcast will be available on the company investor relations Events & Presentations page.
Cybin (NYSE American:CYBN) announced that George Tziras, Chief Business Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, taking place November 10-12, 2025.
The fireside chat will be webcast live on Monday, November 10, 2025 at 4:30 p.m. ET, with an archived webcast available on the company’s investor relations Events & Presentations page.
Cybin (NYSE American: CYBN) announced that Chief Medical Officer Amir Inamdar will participate in a panel at the 2025 Milken Institute Future of Health Summit in Washington, D.C., held November 4–6, 2025.
Panel: Reimagining Mental Health: Innovation at the Intersection of Care and Technology. Date: Wednesday, November 5, 2025. Time: 2:00–3:00 PM ET. The live panel will be accessible via webcast, and an archived recording will be posted on Cybin’s investor relations Events & Presentations page.
Cybin (NYSE American: CYBN) closed a registered direct offering on October 31, 2025 raising aggregate gross proceeds of US$175,009,911.45.
The Company issued 22,277,750 common shares and 4,605,500 pre-funded warrant(s) at US$6.51 each; each security includes 0.35 common share purchase warrant exercisable at US$8.14 until the earlier of June 30, 2027 or certain trial/data or acceleration triggers. Placement agents included Jefferies, TD Cowen, and Cantor. Net proceeds are intended to repay outstanding unsecured convertible debentures held by High Trail, advance CYB003/CYB004/CYB005 programs, and for working capital and general corporate purposes.
Cybin (NYSE American: CYBN) announced a registered direct offering of 22,277,750 common shares and pre-funded warrant equivalents at US$6.51 per share/pre-funded warrant for aggregate gross proceeds of US$175,009,911.45. Each security includes 0.35 warrant exercisable at US$8.14 until June 30, 2027 or earlier on specified trial or market triggers. Proceeds are intended to repay outstanding High Trail convertible debentures in full, advance CYB003, CYB004, and CYB005 clinical programs, and for working capital. The offering is led by Jefferies, TD Cowen, and Cantor and is expected to close on October 31, 2025, subject to exchange approvals and customary conditions.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
